ArticleFrontiers in cardiovascular medicine2026
Association between systemic immune-inflammation index(SII) and all-cause and cardiovascular mortality in heart failure patients: a single-center retrospective analysis.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the association between the systemic immune-inflammatory index (SII) and mortality in patients with heart failure (HF). Method: We conducted a retrospective cohort study of 1,084 HF patients. In this retrospective cohort study, we enrolled patients hospitalized for heart failure between January 2022 and June 2023. Follow-up was conducted via telephone and outpatient visits until death or July 22, 2025, with all-cause and cardiovascular mortality as primary endpoints. Patients were categorized by log-transformed SII (LnSII). Cox models assessed associations between LnSII and mortality, while restricted cubic splines evaluated nonlinearity. Subgroup, mediation (NT-proBNP, LVEF), and sensitivity analyses were performed. Results: A higher LnSII was significantly associated with an increased risk of all-cause mortality (fully adjusted HR = 1.59, 95% CI: 1.03-2.46), No statistically significant association was detected with cardiovascular mortality, which may be attributable to the limited number of cardiovascular deaths ( Conclusion: Elevated SII is independently associated with an increased risk of all-cause mortality in HF patients, particularly among smokers, and may serve as a useful prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.